Literature DB >> 24649018

Expression of set is downregulated by rapamycin in human colorectal cancer cells.

Xiaoxia Wen1, Yao Chen1.   

Abstract

The purpose of this study was to determine the mechanism through which rapamycin treatment affects the expression of the set gene in human colorectal adenocarcinoma cells. The effect of rapamycin treatment on set expression was evaluated by assessing the mRNA and protein expression of set in the SW480 and LoVo human colon carcinoma cell lines following treatment with rapamycin by quantitative polymerase chain reaction (qPCR) and western blot analysis, respectively. Our results demonstrated that the mRNA and protein levels of set were significantly decreased subsequent to rapamycin treatment in the two cell lines, indicating that set expression may be downregulated by rapamycin in human colorectal adenocarcinoma cells. Our findings suggested that the mammalian target of rapamycin signaling pathway may play a role in tumorigenesis through the regulation of the set gene.

Entities:  

Keywords:  human colorectal adenocarcinoma; mammalian target of rapamycin; rapamycin; set

Year:  2013        PMID: 24649018      PMCID: PMC3917056          DOI: 10.3892/br.2013.133

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  21 in total

1.  Identification of differently expressed genes in human colorectal adenocarcinoma.

Authors:  Yao Chen; Yi-Zeng Zhang; Zong-Guang Zhou; Gang Wang; Zeng-Ni Yi
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 2.  mTOR signaling at a glance.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  J Cell Sci       Date:  2009-10-15       Impact factor: 5.285

3.  The set gene is a potential oncogene in human colorectal adenocarcinoma and oral squamous cell carcinoma.

Authors:  Qin Jiang; Chunle Zhang; Jianjun Zhu; Qianming Chen; Yao Chen
Journal:  Mol Med Rep       Date:  2011-07-01       Impact factor: 2.952

4.  The coordinate regulation of the p53 and mTOR pathways in cells.

Authors:  Zhaohui Feng; Haiyan Zhang; Arnold J Levine; Shengkan Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

Review 5.  The promise of mTOR inhibitors in the treatment of colorectal cancer.

Authors:  Dae-Dong Kim; Cathy Eng
Journal:  Expert Opin Investig Drugs       Date:  2012-09-16       Impact factor: 6.206

6.  Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells.

Authors:  Yunlong Lei; Kai Huang; Cong Gao; Quek Choon Lau; Hua Pan; Ke Xie; Jingyi Li; Rui Liu; Tao Zhang; Na Xie; Huey Shan Nai; Hong Wu; Qiang Dong; Xia Zhao; Edouard C Nice; Canhua Huang; Yuquan Wei
Journal:  Mol Cell Proteomics       Date:  2011-05-27       Impact factor: 5.911

7.  Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.

Authors:  M von Lindern; S van Baal; J Wiegant; A Raap; A Hagemeijer; G Grosveld
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

8.  Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells.

Authors:  Naomi Miyake; Hiroki Chikumi; Miyako Takata; Masaki Nakamoto; Tadashi Igishi; Eiji Shimizu
Journal:  Oncol Rep       Date:  2012-06-12       Impact factor: 3.906

9.  Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.

Authors:  Pat Gulhati; Qingsong Cai; Jing Li; Jianyu Liu; Piotr G Rychahou; Suimin Qiu; Eun Y Lee; Scott R Silva; Kanika A Bowen; Tianyan Gao; B Mark Evers
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

10.  SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates.

Authors:  Luciana O Almeida; Renata N Goto; Cezar R Pestana; Sérgio A Uyemura; Silvio Gutkind; Carlos Curti; Andréia M Leopoldino
Journal:  FEBS J       Date:  2012-11-23       Impact factor: 5.542

View more
  2 in total

1.  The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer.

Authors:  Xiaoxia Wen; Jianjun Zhu; Lei Dong; Yao Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

2.  CENPH Inhibits Rapamycin Sensitivity by Regulating GOLPH3-dependent mTOR Signaling Pathway in Colorectal Cancer.

Authors:  Wei Wu; Fan Wu; Zaozao Wang; Jiabo Di; Jie Yang; Pin Gao; Beihai Jiang; Xiangqian Su
Journal:  J Cancer       Date:  2017-07-15       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.